Ark Therapeutics announces board amendments

Ark Therapeutics has revealed plans to make a number of changes to its board of directors following its August 2010 meeting.

The medical technology company has invited Iain Ross to become a non-executive member of the board, subject to approval by shareholders, in addition to becoming a consultant to the firm.

He has previously accrues extensive experience in the healthcare sector in positions at companies such as Sandoz, Celltech Biologics and Phadia, and will be providing Ark Therapeutics with advice on its future financial strategies.

In addition, the company confirmed that Dr Wolfgang Plischke and Sir Mark Richmond will be stepping down from their positions on the board following the August meeting.

The firm said: “Both have contributed greatly to Ark’s development and they will be missed.”

This comes after Ark Therapeuctics appointed David Bowyer as its new chief financial officer in May, while became Dr Edward Bliss company secretary.